Meeting
2015 Gastrointestinal Cancers Symposium
Effect of coadministration of propranolol and etodolac (VT-122) plus sorafenib for patients with advanced hepatocellular carcinoma (HCC).
Authors
Andrew N de la Torre
St. Joseph's Regional Medical Center, Paterson, NJ
Andrew N de la Torre , Ismael Castaneda , Aram F. Hezel , Newell F. Bascomb , Gouri Shankar Bhattacharyya , Ghassan K. Abou-Alfa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01265576
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 390)
DOI
10.1200/jco.2015.33.3_suppl.390
Abstract #
390
Poster Bd #
D9
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A randomized, double-blind, placebo-controlled phase III study of S-1 in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE).
First Author: Masatoshi Kudo
Poster
2018 ASCO Annual Meeting
Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).
First Author: Robin Kate Kelley
Poster
2018 Gastrointestinal Cancers Symposium
Nivolumab in advanced hepatocellular carcinoma (HCC) and Child Pugh B (CPB) cirrhosis: Safety and clinical outcomes in a retrospective case series.
First Author: Swetha Kambhampati
Poster
2015 Gastrointestinal Cancers Symposium
Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426).
First Author: Ghassan K. Abou-Alfa